N 0861

Drug Profile

N 0861

Latest Information Update: 18 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Whitby Pharmaceuticals
  • Developer Aderis Pharmaceuticals (CEASED)
  • Class Antiarrhythmics; Cardiotonics; Neuroprotectants
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Myocardial infarction

Most Recent Events

  • 01 Jun 2005 As a result of corporate merger activities Aderis Pharmaceuticals has ceased operations
  • 08 Dec 1998 Preclinical development for Shock in USA (Unknown route)
  • 08 Dec 1998 A clinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top